A Novel Targeted and High‐Efficiency Nanosystem for Combinational Therapy for Alzheimer's Disease
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) remains the most prevalent neurodegenerative disease, and no effective treatment is available yet. Metal‐ion‐triggered aggregates of amyloid‐beta (A β) peptide and acetylcholine imbalance are reported to be possible factors in AD pathogenesis. Thus, a combination therapy that can not only inhibit and reduce A β aggregation but also simultaneously regulate acetylcholine imbalance that can serve as a potential treatment for AD is needed. Here, clioquinol (metal‐ion chelating agent) and donepezil (acetylcholinesterase (AChE) inhibitor) co‐encapsulated human serum albumin (HSA) nanoparticles (dcHGT NPs) are designed, which are modified with transcriptional activator protein (TAT) and monosialotetrahexosylganglioside (GM1). The GM1 lipid and TAT peptide endow this drug delivery nanosystem with high brain entry efficiency and long‐term retention capabilities through intranasal administration. It is found that dcHGT NPs can significantly inhibit and eliminate A β aggregation, relieve acetylcholine‐related inflammation in microglial cells, and protect primary neurons from A β oligomer‐induced neurotoxicity in vitro. The alleviation of A β‐related inflammation and AChE‐inhibited effect further synergistically adjust acetylcholine imbalance. It is further demonstrated that dcHGT NPs reduce A β deposition, ameliorate neuron morphological changes, rescue memory deficits, and greatly improve acetylcholine regulation ability in vivo. This multifunctional synergetic nanosystem can be a new candidate to achieve highly efficient combination therapy for AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226
Alzheimer's disease: Targeting the Cholinergic System
H. Ferreira-Vieira, T., M. Guimaraes, I., R. Silva, F., & M. Ribeiro, F. (2016) · Current Neuropharmacology · doi:10.2174/1570159x13666150716165726 · Cited by 1,551
Zhang, P., Kishimoto, Y., Grammatikakis, I., Gottimukkala, K., Cutler, R. G., Zhang, S., Abdelmohsen, K., Bohr, V. A., Misra Sen, J., Gorospe, M., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-019-0372-9 · Cited by 977
The role of microglia in amyloid clearance from the AD brain
Lee, C. Y. D., & Landreth, G. E. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0433-4 · Cited by 701
Metal Ions in Alzheimer’s Disease: A Key Role or Not?
Liu, Y., Nguyen, M., Robert, A., & Meunier, B. (2019) · Accounts of Chemical Research · doi:10.1021/acs.accounts.9b00248 · Cited by 353
Pan, X.-D., Zhu, Y.-G., Lin, N., Zhang, J., Ye, Q.-Y., Huang, H.-P., & Chen, X.-C. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-45 · Cited by 292
Tau-Targeted Multifunctional Nanocomposite for Combinational Therapy of Alzheimer’s Disease
Chen, Q., Du, Y., Zhang, K., Liang, Z., Li, J., Yu, H., Ren, R., Feng, J., Jin, Z., Li, F., et al. (2018) · ACS Nano · doi:10.1021/acsnano.7b07625 · Cited by 280
Synaptic markers of cognitive decline in neurodegenerative diseases: a proteomic approach
Bereczki, E., Branca, R. M., Francis, P. T., Pereira, J. B., Baek, J.-H., Hortobágyi, T., Winblad, B., Ballard, C., Lehtiö, J., & Aarsland, D. (2018) · Brain · doi:10.1093/brain/awx352 · Cited by 220
Huang, M., Hu, M., Song, Q., Song, H., Huang, J., Gu, X., Wang, X., Chen, J., Kang, T., Feng, X., et al. (2015) · ACS Nano · doi:10.1021/acsnano.5b03124 · Cited by 127
Cited by
Multifunctional nanoparticle-mediated combining therapy for human diseases
Li, X., Peng, X., Zoulikha, M., Boafo, G. F., Magar, K. T., Ju, Y., & He, W. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01668-1 · Cited by 521
Huang, Q., Jiang, C., Xia, X., Wang, Y., Yan, C., Wang, X., Lei, T., Yang, X., Yang, W., Cheng, G., et al. (2023) · Research · doi:10.34133/research.0180 · Cited by 78
Emerging nanotechnology for Alzheimer's disease: From detection to treatment
Song, N., Sun, S., Chen, K., Wang, Y., Wang, H., Meng, J., Guo, M., Zhang, X.-D., & Zhang, R. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.07.004 · Cited by 44
Self-citationVersatile nanomaterials for Alzheimer’s disease: Pathogenesis inspired disease-modifying therapy
Xi, Y., Chen, Y., Jin, Y., Han, G., Song, M., Song, T., Shi, Y., Tao, L., Huang, Z., Zhou, J., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.02.034 · Cited by 27
Metadata
- Authors
- Yang, H., Mu, W., Wei, D., Zhang, Y., Duan, Y., Gao, J., Gong, X., Wang, H., Wu, X., Tao, H., & Chang, J.
- Venue
- Advanced Science
- Publisher
- Wiley
- Published
- 2020-08-09
- Volume
- 7
- Issue
- 19
- Pages
- 1902906-1902906
- ISSN
- 2198-3844 (ISSN-L)
- OpenAlex
- W3048378890
- Cited by
- 79
- References
- 9
- FWCI
- 5.28
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Novel Targeted and High‐Efficiency Nanosystem for Combinational Therapy for Alzheimer's Disease. https://app.cochat.ai/papers/10.1002/advs.201902906
- The paper
- Yang, H., Mu, W., Wei, D., Zhang, Y., Duan, Y., Gao, J., Gong, X., Wang, H., Wu, X., Tao, H., & Chang, J. (2020). A Novel Targeted and High‐Efficiency Nanosystem for Combinational Therapy for Alzheimer's Disease. Advanced Science. https://doi.org/10.1002/advs.201902906
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.